Pharmacokinetic Herb-Drug Interactions (Part 1): Origins, Mechanisms, and the Impact of Botanical Dietary Supplements

 

 Permissions and Reprints

Abstract

Phytochemicals have been components of man's diet for millennia and are believed to have played a significant role in steering the functional development of xenobiotic metabolizing enzymes and transporters within the human gastrointestinal tract. Only recently, however, have plant secondary metabolites been recognized as modulators of human drug disposition. Despite exposure to thousands of structurally diverse dietary phytochemicals, only a few appear to significantly modulate human drug metabolizing enzymes and transporters. In some instances, these interactions may have beneficial effects like cancer prevention, whereas others may dramatically affect the pharmacokinetics of concomitantly administered drugs. In today's global economy, the opportunity for exposure to more exotic phytochemicals is significantly enhanced. Formulated as concentrated phytochemical extracts, botanical dietary supplements are vehicles for a host of plant secondary metabolites rarely encountered in the normal diet. When taken with conventional medications, botanical dietary supplements may give rise to clinically significant herb-drug interactions. These interactions stem from phytochemical-mediated induction and/or inhibition of human drug metabolizing enzymes and transporters.

References

• 1 Gonzalez F J, Nebert D W. Evolution of the P450 gene superfamily: animal-plant “warfare,” molecular drive and human genetic differences in drug oxidation.  Trends Genet. 1990;  60 265-271
  Google Scholar
• 2 Nebert D W, Nelson D R, Feyereisen R. Evolution of the cytochrome P450 genes.  Xenobiotica. 1989;  19 1149-1160
  Google Scholar
• 3 Bock K W. Veterbrate UDP-glucuronosyl transferases: functional and evolutionary aspects.  Biochem Pharmacol. 2003;  66 691-696
  Google Scholar
• 4 Paulsen I T. Multidrug efflux pumps and resistance: regulation and evolution.  Curr Opin Microbiol. 2003;  6 446-451
  Google Scholar
• 5 Iyer M, Reschly E J, Krasowski M D. Functional evolution of the pregnane X receptor.  Expert Opin Drug Metab Toxicol. 2006;  2 381-397
  Google Scholar
• 6 Makkar H P S, Siddhuraju P, Becker K. Plant secondary metabolites. Totowa: Humana Press; 2007
  Google Scholar
• 7 Harbone J B, Baxter H, Moss G P. Phytochemical dictionary: a handbook of bioactive compounds from plants. 2nd edition. Philadelphia: Taylor & Francis; 1999
  Google Scholar
• 8 Briskin D P. Medicinal plants and phytomedicines. Linking plant biochemistry and physiology to human health.  Plant Physiol. 2000;  124 507-514
  Google Scholar
• 9 Dixon R A. Natural products and plant disease resistance.  Nature. 2001;  411 843-847
  Google Scholar
• 10 Nielsen K A, Moller B L. Cytochrome P450s in plants. In: Ortiz de Montellano P R, editor Cytochrome P450: Structure, mechanism, and biochemistry. 3rd edition. New York: Kluwer Academic/Plenum; 2005: 553-583
  Google Scholar
• 11 Ross J, Li Y, Lim E, Bowles D J. Higher plant glycosyltransferases.  Genome Biol. 2001;  2 3004.1-3004.6
  Google Scholar
• 12 Bowles D, Isayenkova J, Lim E, Poppenberger B. Glycosyltransferases: managers of small molecules.  Curr Opin Plant Biol. 2005;  8 254-263
  Google Scholar
• 13 Bowles D, Lim E-K, Poppenberger B, Vaistij F E. Glycosyltransferases of lipophilic small molecules.  Annu Rev Plant Biol. 2006;  57 567-597
  Google Scholar
• 14 Varin L, Marsolais F, Richard M, Rouleau M. Biochemistry and molecular biology of plant sulfotransferases.  FASEB J. 1997;  11 517-525
  Google Scholar
• 15 Dixon D P, Lapthorn A, Edwards R. Plant glutathione transferases.  Genome Biol. 2002;  3 3004.1-3004.10
  Google Scholar
• 16 Bowles S B, Yu Q. Evolution in action: plants resistant to herbicides.  Annu Rev Plant Biol. 2010;  61 317-347
  Google Scholar
• 17 Siminszky B. Plant cytochrome P450-mediated herbicide metabolism.  Phytochem Rev. 2006;  5 445-458
  Google Scholar
• 18 Yazaki K, Shitan N, Sugiyama A, Takanashi K. Cell and molecular biology of ATP-binding cassette proteins in plants.  Int Rev Cell Mol Biol. 2009;  276 263-299
  Google Scholar
• 19 Yazaki K. Transporters of secondary metabolites.  Curr Opin Plant Biol. 2005;  8 301-307
  Google Scholar
• 20 Sundberg B E, Waag E, Jacobsson J A, Stephansson O, Rumaks J, Svirskis S, Alsio J, Roman E, Ebendal T, Klusa V, Fredriksson R. The evolutionary history and tissue mapping of amino acid transporters belonging to solute carrier families SLC32, SLC36, and SLC38.  J Mol Neurosci. 2008;  35 179-193
  Google Scholar
• 21 Kufner I, Koch W. Stress regulated members of the plant organic cation transporter family are localized to the vacuolar membrane.  BMC Res Notes. 2008;  43 1-10
  Google Scholar
• 22 Danielson P B. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans.  Curr Drug Metab. 2002;  3 561-597
  Google Scholar
• 23 Radominska-Pandya A, Czernik P J, Little J M, Battaglia E, Mackenzie P I. Structural and functional studies of UDP-glucuronosyltransferases.  Drug Metab Rev. 1999;  31 817-899
  Google Scholar
• 24 Eaton D L, Bammler T K. Concise review of the glutathione s-transferases and their significance to toxicology.  Toxicol Sci. 1999;  49 156-164
  Google Scholar
• 25 Huang C, Chen Y, Zhou T, Chen G. Sulfation of dietary flavonoids by human sulfotransferases.  Xenobiotica. 2009;  39 312-322
  Google Scholar
• 26 Kauffman F C. Sulfonation in pharmacology and toxicology.  Drug Metab Rev. 2004;  36 823-843
  Google Scholar
• 27 Klaassen C D, Aleksunes L M. Xenobiotic, bile acid, and cholesterol transporters: function and regulation.  Pharmacol Rev. 2010;  62 1-96
  Google Scholar
• 28 Jones P M, O'Mara M L, George A M. ABC transporters: a riddle wrapped in a mystery inside an enigma.  TIBS. 2009;  34 520-531
  Google Scholar
• 29 Scherrmann J M. Transporters in absorption, distribution, and elimination.  Chem Biodivers. 2009;  6 1933-1942
  Google Scholar
• 30 Ho R H, Kim R B. Transporters and drug therapy: implications for drug disposition and disease.  Clin Pharmacol Ther. 2005;  78 260-277
  Google Scholar
• 31 Lewis D F V, Watson E, Lake B G. Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics.  Mutat Res. 1998;  410 245-270
  Google Scholar
• 32 Schuler M A, Duan H, Bilgin M, Ali S. Arabidopis cytochrome P450s through the looking glass: a window on plant biochemistry.  Phytochem Rev. 2006;  5 205-237
  Google Scholar
• 33 Mandlekar S, Hong J L, Kong A N. Modulation of metabolic enzymes by dietary phytochemicals: a review of mechanisms underlying beneficial versus unfavorable effects.  Curr Drug Metab. 2006;  7 661-675
  Google Scholar
• 34 Li Y, Revalde J L, Reid G, Paxton J W. Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer.  Drug Metab Rev. 2010;  42 590-611
  Google Scholar
• 35 Hernandez J P, Mota L C, Baldwin W S. Activation of CAR and PXR by dietary, environmental and occupational chemicals alters drug metabolism, intermediary metabolism, and cell proliferation.  Curr Pharmacogenomic Person Med. 2009;  7 81-105
  Google Scholar
• 36 Ma Q. Xenobiotic-activated receptors: from transcription to drug metabolism to disease.  Chem Res Toxicol. 2008;  21 1651-1671
  Google Scholar
• 37 Pascussi J M, Gerbal-Chaloin S, Duret C, Daujat-Chavanieu M, Vilarem M J, Maurel P. The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences.  Annu Rev Pharmacol Toxicol. 2008;  48 1-32
  Google Scholar
• 38 Gonzalez F J. The 2006 Bernard B. Brodie Award Lecture: CYP2E1.  Drug Metab Dispos. 2007;  35 1-8
  Google Scholar
• 39 Clarke J D, Dashwood R H, Ho E. Multi-targeted prevention of cancer by sulforaphane.  Cancer Lett. 2008;  269 291-304
  Google Scholar
• 40 Farkas D, Greenblat D J. Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies.  Expert Opin Drug Metab Toxicol. 2008;  4 381-393
  Google Scholar
• 41 Schmiedlin-Ren P, Edwards D J, Fitzsimmons M E, He K, Lown K S, Woster P M, Rahman A, Thummel K E, Fisher J M, Hollenberg P F, Watkins P B. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins.  Drug Metab Dispos. 1997;  25 1228-1233
  Google Scholar
• 42 Guengerich F P, Kim D H, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects.  Chem Res Toxicol. 1991;  4 168-179
  Google Scholar
• 43 Yang C S, Yoo J S, Ishizaki H, Hong J Y. Cytochrome P450IIE1: roles in nitrosamine metabolism and mechanisms of regulation.  Drug Metab Rev. 1990;  22 147-159
  Google Scholar
• 44 Yang C S, Chhabra S K, Hong J Y, Smith T J. Mechanisms of inhibition of chemical toxicity and carcinogenesis by diallyl sulfide (DAS) and related compounds from garlic.  J Nutr. 2001;  131 1041S-1045S
  Google Scholar
• 45 Park K A, Kweon S, Choi H. Anticarcinogenic effect and modification of cytochrome P4502E1 by dietary garlic powder in diethylnitrosamine-initiated rat hepatocarcinogenesis.  J Biochem Mol Biol. 2002;  35 615-622
  Google Scholar
• 46 Gurley B J, Gardner S F, Hubbard M A, Williams D K, Gentry W B, Cui Y, Ang C Y W. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans.  Clin Pharmacol Ther. 2002;  72 276-287
  Google Scholar
• 47 Leclercq I, Desager J P, Horsmans Y. Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress.  Clin Pharmacol Ther. 1998;  64 144-149
  Google Scholar
• 48 Zhang Y, Talalay P. Anticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms.  Cancer Res. 1994;  54 1976s-1981s
  Google Scholar
• 49 Gonzalez F J, Gelboin H V. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins.  Drug Metab Rev. 1994;  26 165-183
  Google Scholar
• 50 Nebert D W. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?.  Am J Hum Genet. 1997;  60 265-271
  Google Scholar
• 51 Neafsey P, Ginsberg G, Hattis D, Sonawane B. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): population distribution of CYP2D6 activity.  J Toxicol Environ Health B. 2009;  12 334-361
  Google Scholar
• 52 Lewis D F V, Eddershaw P J, Goldfarb P S, Tarbit M H. Molecular modeling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism.  Xenobiotica. 1997;  27 319-340
  Google Scholar
• 53 Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.  Pharmacogenomics J. 2005;  5 6-13
  Google Scholar
• 54 Sullivan R J, Hagen E H, Hammerstein P. Revealing the paradox of drug reward in human evolution.  Proc Biol Sci. 2008;  275 1231-1241
  Google Scholar
• 55 Ingelman-Sundberg M. The human genome project and novel aspects of cytochrome P450 research.  Toxicol Appl Pharmacol. 2005;  207 S52-S56
  Google Scholar
• 56 Schmidt B, Ribnicky D M, Poulev A, Logendra S, Cefalu W T, Raskin I. A natural history of botanical therapeutics.  Metab Clin Exp. 2008;  57 S3-S9
  Google Scholar
• 57 Craig W J. Phytochemicals: guardians of our health.  J Am Diet Assoc. 1997;  97 S199-S204
  Google Scholar
• 58 Hu F B. Plant-based foods and prevention of cardiovascular disease: an overview.  Am J Clin Nutr. 2003;  78 544S-551S
  Google Scholar
• 59 Heber D. Vegetables, fruits and phytoestrogens in the prevention of diseases.  J Postgrad Med. 2004;  50 145-149
  Google Scholar
• 60 Graf B A, Milbury P E, Blumberg J B. Flavonols, flavones, flavanones, and human health: epidemiological evidence.  J Med Food. 2005;  8 281-290
  Google Scholar
• 61 Thomasset S C, Berry D P, Garcea G, Marczylo T, Steward W P, Gescher A J. Dietary polyphenolic phytochemicals–promising cancer chemopreventative agents in humans? A review of their clinical properties.  Int J Cancer. 2006;  120 451-458
  Google Scholar
• 62 Kim J, Lee H J, Lee K W. Naturally occurring phytochemicals for the prevention of Alzheimer's disease.  J Neurochem. 2010;  112 1415-1430
  Google Scholar
• 63 Dietary Supplement Health and Education Act (DSHEA), Public Law 103 – 417, 1994; Act 42 U.S.C. 287C–11. 
  Google Scholar
• 64 Gurley B J. Clinical pharmacology and dietary supplements: an evolving relationship.  Clin Pharmacol Ther. 2010;  87 235-238
  Google Scholar
• 65 Barnes P M, Bloom B. Complementary and alternative medicine use among adults and children: United States, 2007. National Health Statistics Reports No 12. Hyattsville: US Department of Health and Human Services; 2008
  Google Scholar
• 66 Nahin R L, Barnes P M, Stussman B J, Bloom B. Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. National Health Statistics Reports No 18. Hyattsville: US Department of Health and Human Services; 2009
  Google Scholar
• 67 Gardiner P, Graham R E, Legedza A T, Eisenberg D M, Phillips R S. Factors associated with dietary supplement use among prescription medication users.  Arch Intern Med. 2006;  166 1968-1974
  Google Scholar
• 68 Wold R S, Lopez S T, Yau L, Butler L M, Pareo-Tubbeh S L, Waters D L, Garry P J, Baumgartner R N. Increasing trends in elderly persons' use of nonvitamin, nonmineral dietary supplements and concurrent use of medications.  J Am Diet Assoc. 2005;  105 54-63
  Google Scholar
• 69 Qato D M, Alexander G C, Conti R M, Johnson M, Schumm P, Lindau S T. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States.  JAMA. 2008;  300 2867-2878
  Google Scholar
• 70 Bruno J J, Ellis J J. Herbal use among US elderly: 2002 National Health Interview Survey.  Ann Pharmacother. 2005;  39 643-648
  Google Scholar
• 71 AARP .What people 50 and older are using and discussing with their physicians. Washington DC: AARP; 2007
  Google Scholar
• 72 Kishiyama S S, Leahy M J, Zitzelberger T A, Guariglia R, Zajdel D P, Calvert J F, Kaye J A, Oken B S. Patterns of dietary supplement usage in demographically diverse older people.  Altern Ther Health Med. 2005;  11 48-53
  Google Scholar
• 73 Foster D F, Phillips R S, Hamel M B, Eisneberg D M. Alternative medicine use in older Americans.  J Am Geriatr Soc. 2000;  48 1560-1565
  Google Scholar
• 74 Mehta D H, Gardiner P M, Phillips R S, McCarthy E P. Herbal and dietary supplement disclosure to health care providers by individuals with chronic conditions.  J Altern Complement Med. 2008;  14 1263-1269
  Google Scholar
• 75 Paine M F, Ludington S S, Chen M L, Stewart P W, Huang S M, Watkins P B. Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression?.  Drug Metab Dispos. 2005;  33 426-433
  Google Scholar
• 76 Canaparo R, Finnstrom N, Serpe L, Nordmark A, Muntoni E, Eandi M, Rane A, Zara G P. Expression of CYP3A isoforms and p-glycoprotein in human stomach, jejunum and ileum.  Clin Exp Pharmacol Physiol. 2007;  34 1138-1144
  Google Scholar
• 77 Niemi M. Role of OATP transporters in the disposition of drugs.  Pharmacogenomics. 2007;  8 787-802
  Google Scholar
• 78 Tomlinson B, Hu M, Lee V W Y. In vivo assessment of herb-drug interactions: possible utility of a pharmacogenetic approach?.  Mol Nutr Food Res. 2008;  52 799-809
  Google Scholar
• 79 Yin O Q P, Tomlinson B, Waye M M Y, Chow A H L, Chow M S S. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole.  Pharmacogenetics. 2004;  14 841-850
  Google Scholar
• 80 Yang L J, Fan L, Liu Z Q, Mao Y M, Guo D, Liu L H, Tan Z R, Peng L, Han C T, Hu D L, Wang D, Zhou H H. Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes.  Eur J Clin Pharmacol. 2009;  65 601-608
  Google Scholar
• 81 Han Y, Guo D, Chen Y, Chen Y, Tan Z R, Zhou H H. Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers.  Eur J Clin Pharmacol. 2009;  65 585-591
  Google Scholar
• 82 Williamson E M. Synergy and other interactions in phytomedicines.  Phytomedicine. 2001;  8 401-409
  Google Scholar
• 83 Gilbert B, Alves L F. Synergy in plant medicines.  Curr Med Chem. 2003;  10 13-20
  Google Scholar
• 84 Obach R S. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression.  J Pharmacol Exp Ther. 2000;  29 88-95
  Google Scholar
• 85 Budzinski J W, Foster B C, Vandenhoek S, Arnason J T. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures.  Phytomedicine. 2000;  7 273-282
  Google Scholar
• 86 Zou L, Harkey M R, Henderson G L. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity.  Life Sci. 2002;  71 1579-1589
  Google Scholar
• 87 Mathews J M, Etheridge A S, Black S R. Inhibition of human cytochrome P450 activities by kava extract and kava lactones.  Drug Metab Dispos. 2002;  30 1153-1157
  Google Scholar
• 88 Foster B C, Vandenhoek S, Hana J, Krantis A, Akhtar M H, Bryan M, Budzinski J W, Ramputh A, Arnason J T. In vitro inhibition of human cytochrome P450–mediated metabolism of marker substrates by natural products.  Phytomedicine. 2003;  10 334-342
  Google Scholar
• 89 Raucy J L. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products.  Drug Metab Dispos. 2003;  31 533-539
  Google Scholar
• 90 Chatterjee P, Franklin M R. Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components.  Drug Metab Dispos. 2003;  31 1391-1397
  Google Scholar
• 91 Iwata H, Tezuka Y, Usia T, Kadota S, Hiratsuka A, Watabe T. Inhibition of human liver microsomal CYP3A4 and CYP2D6 by extracts from 78 herbal medicines.  J Tradit Med. 2004;  21 42-50
  Google Scholar
• 92 Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction.  Rapid Commun Mass Spectrom. 2004;  18 2273-2281
  Google Scholar
• 93 He N, Edeki T. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes.  Am J Ther. 2004;  11 206-212
  Google Scholar
• 94 Zou L, Henderson G L, Harkey M R, Sakai Y, Li A. Effects of kava (kava-kava, ‘Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes.  Phytomedicine. 2004;  11 285-294
  Google Scholar
• 95 Strandell J, Neil A, Carlin G. An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies.  Phytomedicine. 2004;  11 98-104
  Google Scholar
• 96 Gross-Steinmeyer K, Stapleton P L, Liu F, Tracy J H, Bammler T K, Quigley S D, Farin F M, Buhler D R, Safe S H, Strom S C, Eaton D L. Phytochemical-induced changes in gene expression of carcinogen-metabolizing enzymes in cultured human primary hepatocytes.  Xenobiotica. 2004;  34 619-632
  Google Scholar
• 97 von Moltke L L, Weemhoff J L, Bedir E, Khan I A, Harmatz J S, Goldman P, Greenblatt D J. Inhibition of human cytochromes P450 by components of Ginkgo biloba.  J Pharm Pharmacol. 2004;  56 1039-1044
  Google Scholar
• 98 Iwata H, Tezuka Y, Kadota S, Hiratuska A, Watabe T. Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract.  Drug Metab Dispos. 2004;  32 1351-1358
  Google Scholar
• 99 Whitley A C, Sweet D H, Walle T. The dietary polyphenol ellagic acid is a potent inhibitor of hOAT1.  Drug Metab Dispos. 2005;  33 1097-1100
  Google Scholar
• 100 Yale S H, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9.  J Altern Complement Med. 2005;  11 433-439
  Google Scholar
• 101 Scott I M, Leduc R I, Burt A J, Marles R J, Arnason J T, Foster B C. The inhibition of human cytochrome P450 by ethanol extracts of North American botanicals.  Pharm Biol. 2006;  44 315-327
  Google Scholar
• 102 Fuchikami H, Satoh H, Tsujimoto M, Ohdo S, Ohtani H, Sawada Y. Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B.  Drug Metab Dispos. 2006;  34 577-582
  Google Scholar
• 103 Foti R S, Wahlstrom J L, Wienkers L C. The in vitro drug interaction potential of dietary supplements containing multiple herbal components.  Drug Metab Dispos. 2007;  35 185-188
  Google Scholar
• 104 Lee S S, Zhang B, He M L, Chang V S C, Kung H F. Screening of active ingredients of herbal medicine for interaction with CYP450 3A4.  Phytother Res. 2007;  21 1096-1099
  Google Scholar
• 105 Etheridge A S, Black S R, Patel P R, So J, Mathews J M. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents.  Planta Med. 2007;  73 731-741
  Google Scholar
• 106 Raner G M, Cornelious S, Moulick K, Wang Y, Mortensen A, Cech N B. Effects of herbal products and their constituents on human P4502E1 activity.  Food Chem Toxicol. 2007;  45 2359-2365
  Google Scholar
• 107 Hellum B H, Hu Z, Nilsen O G. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes.  Basic Clin Pharmacol Toxicol. 2007;  100 23-30
  Google Scholar
• 108 Hellum B H, Nilsen O G. The in vitro inhibitory potential of trade herbal products on huan CYP2D6-mediated metabolism and the influence of ethanol.  Basic Clin Pharmacol Toxicol. 2007;  101 350-358
  Google Scholar
• 109 Budzinski J W, Trudeau V L, Drouin C E, Panahi M, Arnason J T, Foster B C. Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 cell monolayers by selected commercial-source milk thistle and goldenseal products.  Can J Physiol Pharmacol. 2007;  85 966-978
  Google Scholar
• 110 Budzinski J W, Foster B C, Trudeau V L, Drouin C E, Bafi-Yeboa N, Arnason J T. The interaction of selected phytochemicals, HIV drugs, and commercial-source herbal teas and capsules with human cytochrome P450 3A4 and P-glycoprotein.  Pharm Biol. 2008;  46 53-65
  Google Scholar
• 111 Hellum B H, Nilsen O G. In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products.  Basic Clin Pharmacol Toxicol. 2008;  102 466-475
  Google Scholar
• 112 Engdal S, Nilsen O G. Inhibition of P-glycoprotein in Caco-2 cells: effects of herbal remedies frequently used by cancer patients.  Xenobiotica. 2008;  38 559-573
  Google Scholar
• 113 Satsu H, Hiura Y, Mochizuki K, Hamada M, Shimizu M. Activation of pregnane X receptor and induction of MDR1 by dietary phytochemicals.  J Agric Food Chem. 2008;  56 5366-5373
  Google Scholar
• 114 Roderio I, Donato M T, Jimenez N, Garrido G, Molina-Torres J, Menendez R, Castell J V, Gomez-Lechon M J. Inhibition of human P450 enzymes by natural extracts used in traditional medicine.  Phytother Res. 2009;  23 279-282
  Google Scholar
• 115 Hellum B H, Hu Z, Nilsen O G. Trade herbal products and induction of CYP2C19 and CYP2E1 in cultured human hepatocytes.  Basic Clin Pharmacol Toxicol. 2009;  105 58-63
  Google Scholar
• 116 Tiong K H, Yiap B C, Tan E L, Ismail R, Ong C E. In vitro modulation of naturally occurring flavonoids on cytochrome P450 2A6 (CYP2A6) activity.  Xenobiotica. 2010;  40 458-466
  Google Scholar
• 117 Satsu H, Hiura Y, Mochizuki K, Hamada M, Shimizu M. Activation of pregnane X receptor and induction of MDR1 by dietary phytochemicals.  J Agric Food Chem. 2008;  56 5366-5373
  Google Scholar
• 118 Okura T, Ibe M, Umegaki K, Shinozuka K, Yamada S. Effects of dietary ingredients on function and expression of P-glycoprotein in human intestinal epithelial cells.  Biol Pharm Bull. 2010;  33 255-259
  Google Scholar
• 119 Najar I A, Sachin B S, Sharma S C, Satti N K, Suri K A, Johri R K. Modulation of P-glycoprotein ATPase activity by some phytoconstituents.  Phytother Res. 2010;  24 454-458
  Google Scholar
• 120 Kimura Y, Ito H, Ohnishi R, Hatano T. Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity.  Food Chem Toxicol. 2010;  48 429-435
  Google Scholar
• 121 Sevior D K, Hokkanen J, Tolonen A, Abass K, Tursas L, Pelkonen O, Ahokas J T. Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail.  Xenobiotica. 2010;  40 245-254
  Google Scholar
• 122 Nahrstedt A, Butterweck V. Lessons learned from herbal medicinal products: the example of St John's wort.  J Nat Prod. 2010;  73 1015-1021
  Google Scholar
• 123 Gurley B J, Gardner S F, Hubbard M A. Content versus label claims in ephedra-containing dietary supplements.  Am J Health Syst Pharm. 2000;  57 963-969
  Google Scholar
• 124 Harkey M R, Henderson G L, Gershwin M E, Stern J S, Hackman R M. Variability in commercial ginseng products: an analysis of 25 preparations.  Am J Clin Nutr. 2001;  73 1101-1106
  Google Scholar
• 125 Garrard J, Harms S, Eberly L E, Matiak A. Variations in product choices of frequently purchased herbs.  Arch Intern Med. 2003;  163 2290-2295
  Google Scholar
• 126 Brinker F. Managing and interpreting the complexities of botanical research.  HerbalGram. 2009;  82 42-49
  Google Scholar
• 127 Hines E. Standardizing botanical extracts: can the part exceed the whole?.  Pharm Formul Qual. 1999;  3 28-33
  Google Scholar
• 128 van Breeman R B, Fong H H S, Farnsworth N R. Ensuring the safety of botanical dietary supplements.  Am J Clin Nutr. 2008;  87 509S-513S
  Google Scholar
• 129 Goldman P. Herbal medicines today and the roots of modern pharmacology.  Ann Intern Med. 2001;  135 594-600
  Google Scholar
• 130 Wanwimolruk S, Wong K, Wanwimolruk P. Variable inhibitory effect of different brands of commercial herbal supplements on human cytochrome P-450 CYP3A4.  Drug Metab Drug Interact. 2009;  24 17-35
  Google Scholar
• 131 Gurley B J. Dosage form performance: an overlooked determinant of phytochemical efficacy and safety.  Planta Med. 2010;  76 504
  Google Scholar
• 132 Schulz H U, Schurer M, Krumbiegel G, Wachter W, Weyhenmeyer R, Seidel G. Investigation of dissolution and bioequivalence of silymarin products.  Arzneimittelforschung. 1995;  45 61-64
  Google Scholar
• 133 Westerhoff K, Kaunzinger A, Wurglics M, Dressman J, Schubert-Zsilavecz M. Biorelevant dissolution testing of St John's wort products.  J Pharm Pharmacol. 2002;  54 1615-1621
  Google Scholar
• 134 Nair V D P, Kanfer I. Development of dissolution tests for the quality control of complementary/alternate and traditional medicines: application to African potato products.  J Pharm Pharm Sci. 2008;  11 35-44
  Google Scholar
• 135 United States Pharmacopeial Convention .Disintegration and dissolution of dietary supplements. Rockville; USP 33-NF 28 2010
  Google Scholar
• 136 Current good manufacturing practice in manufacturing, packaging, labeling, or holding operations for dietary supplements; Final rule.  Fed Reg. 2007;  72 34751-34958
  Google Scholar
• 137 Venkataramanan R, Komoroski B, Strom S. In vitro and in vivo assessment of herb drug interactions.  Life Sci. 2006;  78 2105-2115
  Google Scholar
• 138 Markowitz J S, von Moltke L L, Donovan J L. Predicting interactions between conventional medications and botanical products on the basis of in vitro investigations.  Mol Nutr Food Res. 2008;  52 747-754
  Google Scholar
• 139 Ruschitzka F, Meier P J, Turina M, Luscher T F, Noll G. Acute heart transplant rejection due to Saint John's wort.  Lancet. 2000;  355 548-549
  Google Scholar
• 140 Breidenbach T H. Profound drop of cyclosporine A whole blood trough levels caused by St. John's wort (Hypericum perforatum).  Transplantation. 2000;  69 2229-2232
  Google Scholar
• 141 Barone G W, Gurley B J, Ketel B L, Lightfoot M L, Abul-Ezz S R. Drug interaction between St John's wort and cyclosporine.  Ann Pharmacother. 2000;  34 1013-1016
  Google Scholar
• 142 Barone G W, Gurley B J, Ketel B L, Abul-Ezz S R. Herbal dietary supplements: a source for drug interactions in transplant recipients.  Transplantation. 2001;  71 239-241
  Google Scholar
• 143 Moore L B, Goodwin B, Jones S A, Wisely W B, Serabjit-Singh C J, Willson T M, Collins J L, Kliewer S A. St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor.  Proc Natl Acad Sci USA. 2000;  97 7500-7502
  Google Scholar
• 144 Wentworth J M, Agostini M, Love J, Schwabe J W, Chatterjee V K K. St John's wort, a herbal antidepressant, activates the steroid X receptor.  J Endocrinol. 2000;  166 R11-R16
  Google Scholar
• 145 Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum).  Clin Pharmacol Ther. 1999;  66 338-345
  Google Scholar
• 146 Roby C A, Anderson G D, Kantor E, Dryer D A, Burstein A H. St John's wort: effect on CYP3A4 activity.  Clin Pharmacol Ther. 2000;  67 451-457
  Google Scholar
• 147 Wang Z, Gorski C, Hamman M A, Huang S M, Lesko L J, Hall S D. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.  Clin Pharmacol Ther. 2001;  70 317-326
  Google Scholar
• 148 Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakamoto K, Masada M, Miyamori I, Fujimura A. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin.  Clin Pharmacol Ther. 2001;  70 518-524
  Google Scholar
• 149 Hennessy M, Kelleher D, Spiers J P, Kavanagh B P, Back D, Mulcahy F, Feely J. St John's wort increases expression of P-glycoprotein: implications for drug interactions.  Br J Clin Pharmacol. 2002;  53 75-82
  Google Scholar
• 150 Izzo A A. Herb-drug interactions: an overview of the clinical evidence.  Fund Clin Pharmacol. 2004;  19 1-16
  Google Scholar
• 151 Zhou S, Lim L Y, Chowbay B. Herbal modulation of P-glycoprotein.  Drug Metab Rev. 2004;  36 57-104
  Google Scholar
• 152 Delogda R, Westlake A C G. Herbal interactions involving cytochrome P450 enzymes.  Toxicol Rev. 2004;  23 239-249
  Google Scholar
• 153 Mills E, Wu P, Johnston B C, Gallicano K, Clarke M, Guyatt G. Natural health product-drug interactions: a systematic review of clinical trials.  Ther Drug Monit. 2005;  27 549-557
  Google Scholar
• 154 Hu Z, Yang X, Ho P C L, Chan S Y, Heng P W S, Chan E, Duan W, Koh H L, Zhou S. Herb-drug interactions: a literature review.  Drugs. 2005;  65 1239-1282
  Google Scholar
• 155 Johne A, Roots I. Clinical drug interactions with medicinal herbs.  Evid Based Integr Med. 2005;  2 207-228
  Google Scholar
• 156 Ulbricht C, Basch E, Weissner W, Hackman D. An evidence-based systematic review of herb and supplement interactions by the Natural Standard Research Collaboration.  Expert Opin Drug Saf. 2006;  5 719-728
  Google Scholar
• 157 Borrelli F, Capasso R, Izzo A A. Garlic (Allium sativum L.): adverse effects and drug interactions in humans.  Mol Nutr Food Res. 2007;  51 1386-1397
  Google Scholar
• 158 Borrelli F, Izzo A A. Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations.  AAPS J. 2009;  11 710-727
  Google Scholar
• 159 Izzo A A, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review.  Drugs. 2009;  69 1777-1798
  Google Scholar
• 160 Kennedy D A, Seely D. Clinically based evidence of drug-herb interactions: a systematic review.  Expert Opin Drug Saf. 2010;  9 79-124
  Google Scholar
• 161 Gurley B, Hubbard M A, Williams D K, Thaden J, Tong Y, Gentry W B, Breen P, Carrier D J, Cheboyina S. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin.  J Clin Pharmacol. 2006;  46 201-213
  Google Scholar
• 162 Gurley B J, Swain A, Williams D K, Barone G, Battu S K. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St John's wort, echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics.  Mol Nutr Food Res. 2008;  52 772-779
  Google Scholar
• 163 Food and Drug Administration .Drug Interaction Studies–Study Design, Data Analysis, and Implications for Dosing and Labeling. Available at http://www.fda.gov/Drugs/Guidance Compliance Regulatory Information/Guidances/ucm064982.htm. Accessed October 11, 2011
  Google Scholar
• 164 Huang S M, Temple R, Throckmorton D C, Lesko L J. Drug interaction studies: study design, data analysis, and implications for dosing and labeling.  Clin Pharmacol Ther. 2007;  81 298-304
  Google Scholar
• 165 Smolinske S C. Herbal product contamination and toxicity.  J Pharm Pract. 2005;  18 188-208
  Google Scholar
• 166 Ko R. Safety of ethnic & imported herbal and dietary supplements.  Clin Toxicol. 2006;  44 611-616
  Google Scholar
• 167 Cole M R, Fetrow C W. Adulteration of dietary supplements.  Am J Health Syst Pharm. 2003;  60 1576-1580
  Google Scholar
• 168 Fleshner N, Harvey M, Adomat H, Wood C, Eberding A, Hersey K, Guns E. Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors.  J Urol. 2005;  174 636-641
  Google Scholar
• 169 Food and Drug Administration .Warning on body building products marketed as containing steroids or steroid-like substances. Rockville, MD: US Department of Health and Human Services; Available at http://www.fda.gov/ForConsumers/ConsumerUPdates/ucm173739.html Accessed October 11, 2011
  Google Scholar
• 170 Food and Drug Administration .More weight loss products added to consumer alert. Rockville, MD: US Department of Health and Human Services; Available at http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm103184.htm Accessed October 11, 2011
  Google Scholar

Dr. Bill J. Gurley

Department of Pharmaceutical Sciences
University of Arkansas for Medical Sciences
College of Pharmacy

4301 W. Markham St.

Little Rock, Arkansas 72205

United States

Phone: +1 50 16 86 62 79

Fax: +1 50 15 26 65 10

Email: gurleybillyj@uams.edu